

30 June 2010

TENDER RESULTS

The PHARMAC Board (or Chief Executive under delegated authority) has resolved to accept and decline tenders for Sole Subsidised Supply and Hospital Supply Status for some of the products included in the Invitation to Tender dated 21 December 2007, the Invitation to Tender dated 23 December 2008 and the Invitation to Tender dated 4 December 2009.

Some of the pharmaceuticals that will be delisted when the period of sole supply commences may be subject to existing listing contracts with PHARMAC. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts until such time as the pharmaceuticals are delisted and PHARMAC will continue to subsidise their pharmaceuticals accordingly.

Product Notification Forms

Please note that for all changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H) suppliers are required to notify PHARMAC and the Guild by 4pm **12th July 2010**. More information and product notification forms can be downloaded from our website – www.pharmac.govt.nz/schedule.asp.

2007/08 Tender

Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule

1. Tenders awarded to listed pharmaceuticals where no other brand is listed – subsidy changes (where applicable) on **1 August 2010** and Sole Supply Status commences **1 November 2010**.

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	Current Subsidy and price	New tender subsidy	Sole supply brand (Supplier)
Calcium carbonate	Tab 1.25 g (500 mg elemental); 250 tablets, bottle	\$9.18	\$9.08	Calci-Tab 500 (AFT)
Calcium carbonate	Tab 1.5 g (600 mg elemental); 250 tablets, bottle	\$10.33	\$10.18	Calci-Tab 600 (AFT)

Products where no tender is to be awarded for Sole Subsidised Supply or Hospital Supply Status

The PHARMAC Board (or Chief Executive under delegated authority) resolved not to award tenders for Sole Subsidised Supply or Hospital Supply Status for some of the products listed in the Invitation to Tender, dated 21 December 2007.

The decisions were as follows:

Chemical Name	Line Item
Ethinylloestradiol with Levonorgestrel	Tab 20 mcg with levonorgestrel 100 mcg and 7 inert tablets
Ethinylloestradiol with Levonorgestrel	Tab 30 mcg with levonorgestrel 150 mcg and 7 inert tablets
Fluconazole	Oral liq 10 mg per ml
Intra-Uterine Device	IUD
Isosorbide Mononitrate	Tab 20 mg
Isosorbide Mononitrate	Tab long-acting 40 mg

2008/09 Tender

Products where no tender is to be awarded for Sole Subsidised Supply or Hospital Supply Status

The PHARMAC Board (or Chief Executive under delegated authority) resolved not to award tenders for Sole Subsidised Supply or Hospital Supply Status for some of the products listed in the Invitation to Tender, dated 23 December 2008.

The decisions were as follows:

Chemical Name	Line Item
Losartan	Tab 25 mg
Losartan	Tab 50 mg
Losartan	Tab 100 mg
Losartan	Tab 50 mg with hydrochlorothiazide 12.5 mg
Losartan	Tab 100 mg with hydrochlorothiazide 25 mg
Noradrenaline Acid Tartrate	Inj 1 mg per ml, 2 ml
Sodium Bicarbonate	Inj 8.4%, 50 ml
Sodium Bicarbonate	Inj 8.4%, 100 ml
Stavudine	Cap 40 mg

2009/10 Tender

Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule

- Tenders awarded to listed pharmaceuticals where no other brand is listed – subsidy changes (where applicable) on **1 August 2010** and Sole Supply Status commences **1 November 2010**.

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	Current Subsidy and price	New tender subsidy	Sole supply brand (Supplier)
Azathioprine	Inj 50 mg; 1 injection, vial	\$46.33 (\$47.72)	\$60.00	Imuran (Aspen)
Cilazapril with hydrochlorothiazide	Tab 5 mg with hydrochlorothiazide 12.5 mg; 28 tablets, blister	\$6.30	\$5.36	Inhibace Plus (Roche)
Methadone hydrochloride	Tab 5 mg; 10 tablets, blister	\$2.10	\$1.85	Methatabs (API Consumer)

- Tenders awarded to pharmaceuticals where at least one other brand is listed – listing for tender winning brands at the tender subsidy will occur on **1 August 2010**, reference pricing of non-tender winning brands will occur on **1 October 2010** and Sole Subsidised Supply commences on **1 January 2011**.

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	Current Subsidy and price	New tender subsidy	Sole supply brand (Supplier)	Brands affected by reference pricing and delisting
Ascorbic acid	Tab 100 mg; 500 tablets, bottle	\$17.25	\$13.80	Vitala-C (Boucher and Muir)	Apo-Ascorbic Acid (Apotex)
Azathioprine	Tab 50 mg; 100 tablets, blister	\$26.75*	\$18.45	Imuprine (Mylan)	Azamun (Douglas) Imuran (Aspen)
Ceftriaxone sodium**	Inj 1 g; 5 injections, vial	\$5.40 (per injection)	\$10.49 (5 injections)	Aspen Ceftriaxone (Aspen)	AFT (AFT)
Ipratropium bromide	Nebuliser soln, 250 µg per ml, 1 ml; 20 nebuliser solutions, ampoule	\$4.30	\$3.79	Univent (Rex Medical)	Ipratropium Steri-Neb (Airflow)

Chemical Name	Presentation; Pack size and type	Current Subsidy and price	New tender subsidy	Sole supply brand (Supplier)	Brands affected by reference pricing and delisting
Ipratropium bromide	Nebuliser soln, 250 µg per ml, 2 ml; 20 nebuliser solutions, ampoule	\$5.25	\$4.06	Univent (Rex Medical)	Ipratropium Steri-Neb (Airflow)
Indapamide	Tab 2.5 mg; 90 tablets, blister	\$4.00 (per 100 tablets)	\$2.95	Dapa-Tabs (Mylan)	Napamide (Douglas)
Malathion	Liq 0.5%; 200 ml OP, bottle	\$4.99	\$3.79	A-Lices (AFT)	Derbac-M (SSL New Zealand)
Sodium citrate with sodium lauryl sulphoacetate	Enema 90 mg with sodium lauryl sulphoacetate 9 mg per ml, 5 ml; 50 enemas, tube	\$7.30 (per 12 enemas)	\$25.00	Micolette (AFT)	Microlax (Johnson and Johnson)
Terazosin hydrochloride	Tab 1 mg; 28 tablets, blister	\$2.50	\$1.50	Accord (Arrow)	Apo-Terazosin (Apotex)
Terazosin hydrochloride	Tab 2 mg; 28 tablets, blister	\$23.30 (per 500)	\$0.80	Accord (Arrow)	Apo-Terazosin (Apotex)
Terazosin hydrochloride	Tab 5 mg; 28 tablets, blister	\$29.00 (per 500)	\$1.00	Accord (Arrow)	Apo-Terazosin (Apotex)

*There are two different subsidies. The subsidy of the fully funded product is indicated.

**The tender decisions for ceftriaxone sodium 500 mg injection will be notified in the July tender notification.

4. Tenders awarded to an unlisted pharmaceutical – listing for tender winning brand at the tender subsidy will occur on **1 August 2010** and Sole Subsidised Supply commences on **1 November 2010**.

The decision was as follows:

Chemical Name	Presentation; Pack size and type	New tender subsidy	Sole supply brand (Supplier)
Tamsulosin hydrochloride	Cap 400 mg; 30 capsules, blister	\$5.98	Tamsulosin-Rex (Rex Medical)

Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule

5. Tender awarded to a listed pharmaceutical where only the current brand is listed – price change for hospital tender winning brand of the pharmaceutical will occur in Part II of Section H of the Pharmaceutical Schedule on **1 August 2010**; the DV Limit will apply from **1 October 2010**

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	Hospital Supply Brand (Supplier)	Pack Price	DV Limit
Methadone hydrochloride	Tab 5 mg; 10 tablets, blister	Methatabs (API Consumer)	\$1.85	1%

6. Tenders awarded to listed pharmaceuticals where an alternative brand is already listed – listing of the hospital tender winning brand of the pharmaceuticals will occur in Part II of Section H of the Pharmaceutical Schedule on **1 August 2010**; DV Limits will apply from **1 October 2010**; delisting of the other brands in Section H will occur on **1 October 2010**.

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	Hospital Supply Brand (Supplier)	Pack Price	DV Limit
Ceftriaxone sodium*	Inj 1 g; 5 injections, vial	Aspen Ceftriaxone (Aspen)	\$10.49	1%
Ipratropium bromide	Nebuliser soln, 250 µg per ml, 1 ml; 20 nebuliser solutions, ampoule	Univent (Rex Medical)	\$3.79	1%
Ipratropium bromide	Nebuliser soln, 250 µg per ml, 2 ml; 20 nebuliser solutions, ampoule	Univent (Rex Medical)	\$4.06	1%
Indapamide	Tab 2.5 mg; 90 tablets, blister	Dapa-Tabs (Mylan)	\$2.95	1%
Sodium citrate with sodium lauryl sulphoacetate	Enema 90 mg with sodium lauryl sulphoacetate 9 mg per ml, 5 ml; 50 enemas, tube	Micolette (AFT)	\$25.00	1%

*Tender decisions for ceftriaxone sodium 500 mg injection and 2 g infusion will be notified in the July tender notification.

7. Tenders awarded to pharmaceuticals where no brand is listed - listing of the hospital tender winning brand of the pharmaceuticals will occur in Part II of Section H of the Pharmaceutical Schedule on **1 August 2010** and DV Limits will apply from **1 October 2010**.

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	Hospital Supply Brand (Supplier)	Pack Price	DV Limit
Ascorbic acid	Tab 100 mg; 500 tablets, bottle	Vitala-C (Boucher and Muir)	\$13.80	1%
Azathioprine	Inj 50 mg; 1 injection, vial	Imuran (Aspen)	\$60.00	1%
Azathioprine	Tab 50 mg; 100 tablets, blister	Imuprine (Mylan)	\$18.45	1%
Tamsulosin hydrochloride	Cap 400 mg; 30 capsules, blister	Tamsulosin-Rex (Rex Medical)	\$5.98	1%

Products where no tender is to be awarded for Sole Subsidised Supply or Hospital Supply Status

The PHARMAC Board (or Chief Executive under delegated authority) resolved not to award tenders for Sole Subsidised Supply or Hospital Supply Status for some of the products listed in the Invitation to Tender dated 4 December 2009.

The decisions were as follows:

Chemical Name	Line Item
Doxazosin Mesylate	Tab 2 mg
Doxazosin Mesylate	Tab 4 mg
Ephedrine	Inj 30 mg per ml, 1 ml
Ephedrine	Inj 30 mg per ml, 10 ml prefilled syringe
Methadone Hydrochloride	Inj 10 mg per ml, 1 ml
Naproxen	Tab long-acting 750 mg
Naproxen	Tab long-acting 1,000 mg
Naproxen Sodium	Tab 275 mg
Naproxen Sodium	Tab 550 mg
Pethidine Hydrochloride	Inj 50 mg per ml, 1 ml
Pethidine Hydrochloride	Inj 50 mg per ml, 2 ml
Sodium Chloride	Inj 0.9%, 5 ml
Sodium Chloride	Inj 0.9%, 10 ml
Sodium Chloride	Inj 0.9%, 20 ml

Please note that all products included in the Invitation to Tender dated 21 December 2007 have now been resolved. For the remaining products in the Invitation to Tender dated 23 December 2008 and the Invitation to Tender dated 4 December 2009 where no announcement has been made, either a decision is still pending, or is provisional and subject to the product gaining market approval and having sufficient stock.

We will keep you informed regarding any changes for the remaining tender products as further decisions are made. If you have any queries regarding this notification please contact PHARMAC on 0800 66 00 50.